Type I IFN receptor controls activated TYK2 in the nucleus: Implications for EAE therapy. Ahmed CM, Noon-Song EN, Kemppainen K, Pascalli MP, Johnson HM J Neuroimmunol. 2012 Oct 27. PMID: 23110939. Abstract CommentRecommendBookmarkWatch